REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by Wall Street Zen

REGENXBIO (NASDAQ:RGNX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Stifel Nicolaus raised their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of REGENXBIO in a research note on Thursday. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday. Finally, Barclays initiated coverage on shares of REGENXBIO in a report on Tuesday. They issued an “overweight” rating and a $37.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

REGENXBIO Stock Down 3.8%

NASDAQ:RGNX opened at $11.16 on Friday. REGENXBIO has a 52 week low of $5.03 and a 52 week high of $16.19. The company has a fifty day simple moving average of $13.72 and a two-hundred day simple moving average of $11.31. The company has a market cap of $564.92 million, a price-to-earnings ratio of -3.22 and a beta of 1.07.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The firm had revenue of $29.73 million during the quarter, compared to analyst estimates of $24.41 million. On average, analysts expect that REGENXBIO will post -4.84 EPS for the current year.

Institutional Trading of REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. Jones Financial Companies Lllp boosted its holdings in shares of REGENXBIO by 44.4% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,270 shares in the last quarter. Profund Advisors LLC lifted its position in REGENXBIO by 11.8% in the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 1,523 shares during the last quarter. Pale Fire Capital SE boosted its stake in REGENXBIO by 7.7% in the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 2,000 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of REGENXBIO during the third quarter worth about $25,000. Finally, Diversified Trust Co. grew its holdings in shares of REGENXBIO by 24.3% during the fourth quarter. Diversified Trust Co. now owns 13,378 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,615 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Key REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.